| 1.19 -0.16 (-11.85%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.42 | 1-year : | 4.7 |
| Resists | First : | 2.92 | Second : | 4.03 |
| Pivot price | 1.68 | |||
| Supports | First : | 1.14 | Second : | 0.95 |
| MAs | MA(5) : | 1.93 |
MA(20) : | 1.58 |
| MA(100) : | 1.13  |
MA(250) : | 1.01 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 5.2 |
D(3) : | 19.8 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 4.03 | Low : | 0.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRLD ] has closed above bottom band by 30.4%. Bollinger Bands are 427.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.33 - 1.34 | 1.34 - 1.35 |
| Low: | 1.17 - 1.18 | 1.18 - 1.19 |
| Close: | 1.17 - 1.19 | 1.19 - 1.2 |
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Sat, 08 Nov 2025
Prelude Therapeutics (PRLD): Valuation Snapshot Following Incyte Deal and Pipeline Realignment - Yahoo Finance
Wed, 05 Nov 2025
Prelude Therapeutics (PRLD) Is Up 14.3% After Incyte Option Deal and Pipeline Shift Has the Bull Case Changed? - Yahoo Finance
Tue, 04 Nov 2025
Major Shift in PRLD Stock: What’s Behind the Surge? - StocksToTrade
Tue, 04 Nov 2025
Prelude Therapeutics’ Stock Performance: Rise or Risk? - timothysykes.com
Tue, 04 Nov 2025
Prelude Therapeutics pauses clinical development of SMARCA2 degrader program (PRLD:NASDAQ) - Seeking Alpha
Tue, 04 Nov 2025
Prelude Therapeutics Announces Management Changes - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 2.917e+007 (%) |
| Held by Institutions | 11.3 (%) |
| Shares Short | 538 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.3325e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 928.6 % |
| Return on Equity (ttm) | -49.8 % |
| Qtrly Rev. Growth | 7e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -75.86 |
| EBITDA (p.s.) | 5.51181e+006 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -108 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 1.51 |
| Dividend | 0 |
| Forward Dividend | 515090 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|